TY - JOUR
T1 - Longitudinal assessment of proximal tubular dysfunction in HIV seropositive and seronegative persons
T2 - Correlates and implications
AU - Sheets, Kerry M.
AU - Atta, Mohamed G.
AU - Fine, Derek M.
AU - Zook, Katie
AU - McFall, Allison M.
AU - Estrella, Michelle M.
AU - Schwartz, George J.
AU - Lucas, Gregory M.
N1 - Funding Information:
Supported by the National Institute on Drug Abuse (R01DA026770, K24DA035684). Other support was provided by the National Institute of Allergy and Infectious Diseases (T32AI102623), the National Institute of Diabetes and Digestive and Kidney Disease (U01DK082194, P01DK056492), the Johns Hopkins Institute for Clinical and Translational Research (ICTR), which is funded in part by grant number UL1-TR000424 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH, and by the Johns Hopkins Center for AIDS Research (P30AI094189). GE Healthcare provided the iohexol used for glomerular filtration rate measurements.
Publisher Copyright:
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2017
Y1 - 2017
N2 - Background: Proximal tubular dysfunction (PTD) is common in HIV-positive persons and has been associated with tenofovir disoproxil fumarate (TDF). However, few studies have assessed the natural history PTD in HIV-positive and-negative individuals, or the association of PTD with the subsequent trajectory of directly measured glomerular filtration rate (mGFR). Methods: We followed 192 HIV-positive and 100 HIV-negative, nondiabetic participants for 3 years. We measured 3 PTD markers (normoglycemic glycosuria, fractional excretion of phosphorus, and tubular proteinuria) and mGFR (by iohexol disappearance from serum) annually. We used univariate and multivariate generalized estimating equation logistic regression to identify factors associated with PTD across all visits and linear mixed effects models to assess the association between baseline PTD and mGFR slope. Results: Compared with HIV-negative participants, HIV-positive persons that were not taking antiretroviral therapy were at increased risk of PTD (adjusted odds ratio 3.33; 95% confidence interval: 1.65 to 6.71), whereas those taking a TDF-based or a TDF-sparing regimen were not at significantly increased risk of PTD. Among HIV-positive participants, uncontrolled viremia was a strong correlate of PTD. Forty-nine of 55 (89%) participants with PTD at baseline had at least 1 subsequent visit without PTD. There was no association between baseline PTD and rate of decline in mGFR over time. Conclusions: Poorly controlled HIV may be a stronger risk factor for PTD than TDF use. The individual-level variability of the PTD markers over time was high, potentially limiting their usefulness for routine screening in unselected patients. Baseline PTD was not associated with subsequent mGFR slope.
AB - Background: Proximal tubular dysfunction (PTD) is common in HIV-positive persons and has been associated with tenofovir disoproxil fumarate (TDF). However, few studies have assessed the natural history PTD in HIV-positive and-negative individuals, or the association of PTD with the subsequent trajectory of directly measured glomerular filtration rate (mGFR). Methods: We followed 192 HIV-positive and 100 HIV-negative, nondiabetic participants for 3 years. We measured 3 PTD markers (normoglycemic glycosuria, fractional excretion of phosphorus, and tubular proteinuria) and mGFR (by iohexol disappearance from serum) annually. We used univariate and multivariate generalized estimating equation logistic regression to identify factors associated with PTD across all visits and linear mixed effects models to assess the association between baseline PTD and mGFR slope. Results: Compared with HIV-negative participants, HIV-positive persons that were not taking antiretroviral therapy were at increased risk of PTD (adjusted odds ratio 3.33; 95% confidence interval: 1.65 to 6.71), whereas those taking a TDF-based or a TDF-sparing regimen were not at significantly increased risk of PTD. Among HIV-positive participants, uncontrolled viremia was a strong correlate of PTD. Forty-nine of 55 (89%) participants with PTD at baseline had at least 1 subsequent visit without PTD. There was no association between baseline PTD and rate of decline in mGFR over time. Conclusions: Poorly controlled HIV may be a stronger risk factor for PTD than TDF use. The individual-level variability of the PTD markers over time was high, potentially limiting their usefulness for routine screening in unselected patients. Baseline PTD was not associated with subsequent mGFR slope.
KW - Antiretroviral therapy
KW - Glomerular filtration rate
KW - HIV
KW - Proximal tubular dysfunction
KW - Tenofovir disoproxil fumarate
UR - http://www.scopus.com/inward/record.url?scp=85011692865&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011692865&partnerID=8YFLogxK
U2 - 10.1097/QAI.0000000000001302
DO - 10.1097/QAI.0000000000001302
M3 - Article
C2 - 28151777
AN - SCOPUS:85011692865
SN - 1525-4135
VL - 75
SP - 45
EP - 51
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
IS - 1
ER -